Douglas D. Cary

Mr. Cary founded the Company and has worked full-time as its President and Chief Executive Officer since October 1994.

Mr. Cary has pharmaceutical industry experience in research and development and business development. This experience has been gained at large and medium-sized pharmaceutical companies as well as at start-up ventures. Mr. Cary has participated in the identification, development and commercialization of pharmaceutical products, has developed comprehensive product market plans and launched new products, established strategic alliances, and has performed due diligence for the acquisition of technologies and companies.

From 1990 to 1994, Mr. Cary served as Vice President of Fuisz Technologies, Inc., a venture-capital-funded start-up company specializing in the development of broadly patented technologies with applications in the pharmaceutical, food, and confection industries. During that time, he was responsible for research and development, business development, quality assurance, and sales and marketing. In addition, he participated in a private placement to fund the company (CIBC Oppenheimer & Co., underwriter). From 1973 to 1985 and again from 1988 to 1990, Mr. Cary held numerous management positions at Abbott Laboratories, where he had responsibilities in new business development and research and development. While at Abbott, he was responsible for the development of AddVantage® (annual sales of over $100 million) and Patient-Controlled Analgesia® (annual sales of over $150 million). Mr. Cary also was Director of Business Development for LyphoMed, Inc., a manufacturer of generic injectable drug products, from 1985 to 1987.

Mr. Cary earned a Master in Business Administration with Honors from Roosevelt University (Chicago) and was elected to Beta Gamma Sigma, a business honorary society. He earned a Bachelor of Science degree in pharmacy from the University of Nebraska and a Bachelor of Arts degree from Hastings College.